CGTX

Business Context and Reporting Period

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company developing disease-modifying therapies for age-related degenerative diseases of the central nervous system and retina. The company's lead product candidate, CT1812, targets the sigma-2 receptor complex to treat Alzheimer's disease and dementia with Lewy bodies. This Form 10-Q covers the quarterly period ended September 30, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Expansion: The net loss for the nine months ended September 30, 2024, increased to $26.1 million from $17.6 million in the prior year period. This was driven by a $7.9 million increase in operating expenses, primarily due to higher clinical program costs ($10.4 million increase) and personnel costs ($1.4 million increase).
• Grant Income Decline: Grant income decreased by $1.5 million year-over-year for the nine-month period, correlating with a decrease in eligible reimbursable costs incurred during 2024 compared to 2023.
• Capital Raises: In March 2024, the company completed a follow-on public offering, raising net proceeds of approximately $11.9 million. Additionally, the company raised approximately $0.9 million through its At-The-Market (ATM) sales agreement during the nine months ended September 30, 2024.
• Subsidiary Liquidation: The company ceased operations and liquidated its wholly-owned Australian subsidiary in January 2024, resulting in a one-time loss on currency translation of $0.2 million recorded in the nine-month period.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for the twelve months following the issuance of this report. As of November 13, 2024, cash on hand ($22.0 million) is not sufficient to fund operations for one year beyond the filing date.
• Liquidity Runway: Based on current business plans, existing cash and grant income are expected to fund operations into the second quarter of 2025, assuming no usage of remaining ATM or Lincoln Park equity line facilities.
• Nasdaq Listing Compliance: The company received a deficiency letter from Nasdaq on September 12, 2024, regarding its stock price trading below the $1.00 minimum bid price for 30 consecutive days. The company has until March 11, 2025, to regain compliance or risk delisting.
• Clinical Outlook: The company reported results from the Phase 2 SHINE trial for CT1812 in Alzheimer's disease, showing a 39% slowing of cognitive decline compared to placebo. Topline results for the Phase 2 SHIMMER trial in dementia with Lewy bodies are expected by year-end 2024.
• Financing Needs: The company expects to continue incurring significant losses and will require substantial additional funding through equity offerings, debt financings, or collaborations to advance its pipeline and maintain operations.

Investor Verification Checklist

• Verify the sufficiency of the $22.0 million cash balance against the projected burn rate and the timeline to Q2 2025.
• Monitor the status of the Nasdaq deficiency notice and the company's plan to regain compliance (e.g., reverse stock split) by March 2025.
• Review the upcoming topline results of the SHIMMER trial (expected late 2024) for CT1812 in dementia with Lewy bodies.
• Assess the availability and terms of the remaining $33.8 million ATM facility and $34.8 million Lincoln Park equity line as potential liquidity backstops.
• Confirm the status of future National Institute of Aging (NIA) grant funding, which has historically been a significant non-dilutive revenue source.